AI assistant
Dare Bioscience, Inc. — Director's Dealing 2016
Jan 12, 2016
34825_dirs_2016-01-12_dfa9d658-f00f-446e-8bbd-247ec22d233e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2016-01-08
Reporting Person: WALT DAVID R (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-01-08 | Common Stock | P | 4500 | $2.8749 | Acquired | 49592 | Direct |
| 2016-01-11 | Common Stock | P | 4355 | $2.8637 | Acquired | 53947 | Direct |
Footnotes
F1: These purchases were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2015.
F2: Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.82 to $2.96 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.81 to $2.94 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.